Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Toxins

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...

Toxic Reactions: Overview

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Toxicity Testing in Animals

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Electrooptic Fabry-Perot filter: development for the study of solar oscillations.

Applied optics·2010

Same author

Assessing risk using different cholesterol-screening methods.

Public health·2004

Same author

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001

Same author

Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.

The oncologist·2001

Same author

Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.

Blood·2000

Same author

Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000

Search research articles

Related Experiment Video

Updated: Jul 23, 2026

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability

Published on: June 21, 2015

Risk/benefit profile of arsenic trioxide.

D M Rust¹, S L Soignet

¹Acute Care Nurse Practitioner Program (Oncology Subspecialty), School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

|May 2, 2001

Summary

Arsenic trioxide offers a new treatment for acute promyelocytic leukemia (APL) relapse, showing effectiveness in U.S. trials. This approach provides a viable option for patients resistant to standard chemotherapy.

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Standard chemotherapy for acute promyelocytic leukemia (APL) has a relapse rate of 20%-30%.
Arsenic trioxide has demonstrated efficacy in achieving complete remission for APL patients in previous studies.
Conventional therapies for APL include all-trans retinoic acid and anthracycline-based chemotherapy.

Purpose of the Study:

To evaluate the safety and efficacy of arsenic trioxide in U.S. patients with relapsed acute promyelocytic leukemia (APL).
To confirm findings from earlier pilot studies on arsenic trioxide treatment for APL.

Main Methods:

A multicenter clinical trial was conducted involving 40 patients with relapsed APL.
Patients received arsenic trioxide following conventional therapy failure.

More Related Videos

In Vitro Scratch Assay to Demonstrate Effects of Arsenic on Skin Cell Migration

In Vitro Scratch Assay to Demonstrate Effects of Arsenic on Skin Cell Migration

Published on: February 23, 2019

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster

Published on: March 24, 2023

Related Experiment Videos

Last Updated: Jul 23, 2026

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability

Published on: June 21, 2015

In Vitro Scratch Assay to Demonstrate Effects of Arsenic on Skin Cell Migration

In Vitro Scratch Assay to Demonstrate Effects of Arsenic on Skin Cell Migration

Published on: February 23, 2019

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster

Published on: March 24, 2023

Data from a prior 12-patient pilot study were also considered.

Main Results:

The multicenter trial confirmed the positive safety and efficacy of arsenic trioxide in relapsed APL.
Common adverse events included hyperleukocytosis, APL differentiation syndrome, prolonged QT interval, skin rash, and hyperglycemia.
The treatment demonstrated successful outcomes in patients who had relapsed after standard chemotherapy.

Conclusions:

Arsenic trioxide is a safe and effective treatment option for patients with relapsed acute promyelocytic leukemia (APL).
This agent provides a valuable alternative for APL patients who do not respond to or relapse after standard chemotherapy regimens.